The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Open accessAbstract
BACKGROUND: In patients with severe hemophilia B, gene therapy that is mediated by a novel self-complementary adeno-associated virus serotype 8 (AAV8) vector has been shown to raise factor IX levels for periods of up to 16 months. We wanted to determine the durability of transgene expression, the vector dose-response relationship, and the level of persistent or late toxicity. METHODS: We evaluated the stability of transgene expression and long-term safety in 10 patients with severe hemophilia B: 6 patients who had been enrolled in an initial phase 1 dose-escalation trial, with 2 patients each receiving a low, intermediate, or high dose, and 4 additional patients who received the high dose (2×10(12) vector genomes per kilogram of body weight). The patients subsequently underwent extensive clinical and laboratory monitoring. RESULTS: A single intravenous infusion of vector in all 10 patients with severe hemophilia B resulted in a dose-dependent increase in circulating factor IX to a level that was 1 to 6% of the normal value over a median period of 3.2 years, with observation ongoing. In the high-dose group, a consistent increase in the factor IX level to a mean (±SD) of 5.1±1.7% was observed in all 6 patients, which resulted in a reduction of more than 90% in both bleeding episodes and the use of prophylactic factor IX concentrate. A transient increase in the mean alanine aminotransferase level to 86 IU per liter (range, 36 to 202) occurred between week 7 and week 10 in 4 of the 6 patients in the high-dose group but resolved over a median of 5 days (range, 2 to 35) after prednisolone treatment. CONCLUSIONS: In 10 patients with severe hemophilia B, the infusion of a single dose of AAV8 vector resulted in long-term therapeutic factor IX expression associated with clinical improvement. With a follow-up period of up to 3 years, no late toxic effects from the therapy were reported. (Funded by the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov number, NCT00979238.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further studies confirmed that the capsid-specific immune response is dose-dependent and administration of low vector doses of AAV are more likely to induce mild inflammation that is manageable by steroids [86–88].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [87]
In the citing paper
“The initial clinical studies of AAV-based gene transfer targeting liver correlated the AAV-specific cytotoxic T lymphocytes activation with transaminitis and loss of transgene expression”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [39]
In the citing paper
“therefore studies of AAV immunogenicity focused mainly on the adaptive immune responses against AAV-transduced hepatocytes (38, 39).”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [39]
In the citing paper
“Moreover, a recent meta-analysis of clinical trials using hepatic AAV gene transfer concluded that vectors rich in CpG motifs results in failure to achieve sustained expression, owing to activation of capsid specific CD8+ T cells (19–22).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [19]
In the citing paper
“Antibody formation against capsid was also not impacted by CpG depletion in clinical trials (19, 57).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [19]
In the citing paper
“These studies however build evidence that short-course CCS alone is likely to be insufficient to inhibit formation of capsid-reactive T cells (13) and rAAV-mediated immune response with systemic high dosages.”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [13]
In the citing paper
“In the subsequent study using AAV8, administration of steroids was able to negate this response and maintain therapeutic FIX levels albeit a 50-70% decline from peak levels (13).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationAAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Self-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Self-citationSnyder, R. O., Miao, C. H., Patijn, G. A., Spratt, S. K., Danos, O., Nagy, D., Gown, A. M., Winther, B., Meuse, L. A., Cohen, L. K., et al. (1997) · Nature Genetics · doi:10.1038/ng0797-270 · Cited by 579
Self-citationHerzog, R. W., Yang, E. Y., Couto, L. B., Hagstrom, J. N., Elwell, D., Fields, P. A., Burton, M., Bellinger, D. A., Read, M. S., Brinkhous, K. M., et al. (1999) · Nature Medicine · doi:10.1038/4743 · Cited by 554
Self-citationHerzog, R. W., Hagstrom, J. N., Kung, S.-H., Tai, S. J., Wilson, J. M., Fisher, K. J., & High, K. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5804 · Cited by 474
Self-citationNathwani, A. C., Gray, J. T., Ng, C. Y., Zhou, J., Spence, Y., Waddington, S. N., Tuddenham, E. G. D., Kemball‐Cook, G., McIntosh, J., Boon‐Spijker, M., et al. (2005) · Blood · doi:10.1182/blood-2005-10-4035 · Cited by 419
Self-citationNathwani, A. C., Rosales, C., McIntosh, J., Rastegarlari, G., Nathwani, D., Raj, D., Nawathe, S., Waddington, S. N., Bronson, R., Jackson, S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.274 · Cited by 345
Self-citationNathwani, A. C., Gray, J. T., McIntosh, J., Ng, C. Y., Zhou, J., Spence, Y., Cochrane, M., Gray, E., Tuddenham, E. G. D., & Davidoff, A. M. (2006) · Blood · doi:10.1182/blood-2006-03-010181 · Cited by 269
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,001
Advances in the management of haemophilia: emerging treatments and their mechanisms
Okaygoun, D., Oliveira, D. D., Soman, S., & Williams, R. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00760-4 · Cited by 77
Srivastava, A. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.014 · Cited by 68
Ding, W. Y., Kuzmuk, V., Hunter, S., Lay, A. C., Hayes, B., Beesley, M., Rollason, R., Hurcombe, J., Barrington, F., Masson, C., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abc8226 · Cited by 75
Self-citationMücke, M. M., Fong, S., Foster, G. R., Lillicrap, D., Miesbach, W., & Zeuzem, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.10.029 · Cited by 73
Gene therapy for immune tolerance induction in hemophilia with inhibitors
Arruda, V. R., & Samelson-Jones, B. J. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13331 · Cited by 72
Ronzitti, G., Bortolussi, G., van Dijk, R., Collaud, F., Charles, S., Leborgne, C., Vidal, P., Martin, S., Gjata, B., Sola, M. S., et al. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.49 · Cited by 72
Self-citationHughes, M. P., Smith, D. A., Morris, L., Fletcher, C., Colaço, A., Huebecker, M., Tordo, J., Palomar, N., Massaro, G., Henckaerts, E., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy212 · Cited by 69
Clinical advances in gene therapy updates on clinical trials of gene therapy in haemophilia
Peyvandi, F., & Garagiola, I. (2019) · Haemophilia · doi:10.1111/hae.13816 · Cited by 71
Manini, A., Abati, E., Nuredini, A., Corti, S. P., & Comi, G. P. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.814174 · Cited by 76
CNS-restricted Transduction and CRISPR/Cas9-mediated Gene Deletion with an Engineered AAV Vector
Murlidharan, G., Sakamoto, K., Rao, L., Corriher, T., Wang, D., Gao, G., Sullivan, P. M., & Asokan, A. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.49 · Cited by 69
Wang, L., Yang, Y., Breton, C. A., Bell, P. L., Li, M., Zhang, J., Che, Y., Saveliev, A., He, Z., White, J., et al. (2020) · Science Advances · doi:10.1126/sciadv.aax5701 · Cited by 67
The Effect of CpG Sequences on Capsid-Specific CD8+ T Cell Responses to AAV Vector Gene Transfer
Xiang, Z., Kurupati, R. K., Li, Y., Kuranda, K., Zhou, X., Mingozzi, F., High, K. A., & Ertl, H. C. J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.014 · Cited by 67
Self-citationTLR9 signaling mediates adaptive immunity following systemic AAV gene therapy
Ashley, S. N., Somanathan, S., Giles, A. R., & Wilson, J. M. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2019.103997 · Cited by 67
Advances in biological therapies for dyslipidemias and atherosclerosis
Valanti, E.-K., Dalakoura-Karagkouni, K., Siasos, G., Kardassis, D., Eliopoulos, A. G., & Sanoudou, D. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154461 · Cited by 68
Fischell, J. M., & Fishman, P. S. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.747726 · Cited by 66
Haemophilia B: Where are we now and what does the future hold?
Dolan, G., Benson, G. M., Duffy, A., Hermans, C. R. J. R., Jiménez‐Yuste, V., Lambert, T., Ljung, R. C. R., Morfini, M., & Šalek, S. Z. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.08.007 · Cited by 67
Evolving AAV-delivered therapeutics towards ultimate cures
He, X., Urip, B. A., Zhang, Z., Ngan, C. C., & Feng, B. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-02034-2 · Cited by 70
Coppens, M., Pipe, S. W., Miesbach, W., Astermark, J., Recht, M., van der Valk, P., Ewenstein, B. M., Pinachyan, K., Galante, N. J., Quellec, S. L., et al. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00006-1 · Cited by 66
Self-citationThree-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A
Madan, B., Ozelo, M. C., Raheja, P., Symington, E., Quon, D. V. K., Leavitt, A. D., Pipe, S. W., Lowe, G., Kenet, G., Reding, M. T., et al. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.04.001 · Cited by 68
Lévy, C., Fusil, F., Amirache, F., Costa, C., Girard-Gagnepain, A., Négre, D., Bernadin, O., Garaulet, G., Rodrı́guez, A., Nair, N., et al. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13520 · Cited by 70
Potential for cellular stress response to hepatic factor VIII expression from AAV vector
Zolotukhin, I., Markusic, D. M., Palaschak, B., Hoffman, B. E., Srikanthan, M. A., & Herzog, R. W. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.63 · Cited by 65
Standard screening methods underreport AAV-mediated transduction and gene editing
Lang, J. F., Toulmin, S. A., Brida, K. L., Eisenlohr, L. C., & Davidson, B. L. (2019) · Nature Communications · doi:10.1038/s41467-019-11321-7 · Cited by 65
Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B
Reiss, U. M., Davidoff, A. M., Tuddenham, E. G. D., Chowdary, P., McIntosh, J., Muczynski, V., Journou, M., Simini, G., Ireland, L., Mohamed, S., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2414783 · Cited by 69
Self-citationAronson, S. J., Veron, P., Collaud, F., Hubert, A., Delahais, V., Honnet, G., de Knegt, R. J., Junge, N., Baumann, U., Giorgio, A. D., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.143 · Cited by 66
Self-citationStrobel, B., Duechs, M. J., Blazevic, D., Rechtsteiner, P., Braun, C., Kroker, K. S., Schmid, B., Ciossek, T., Gottschling, D., Hartig, J. S., et al. (2020) · ACS Synthetic Biology · doi:10.1021/acssynbio.9b00410 · Cited by 61
Ethical and regulatory aspects of genome editing
Kohn, D. B., Porteus, M. H., & Scharenberg, A. M. (2016) · Blood · doi:10.1182/blood-2016-01-678136 · Cited by 70
Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome
Collaud, F., Bortolussi, G., Guianvarc’h, L., Aronson, S. J., Bordet, T., Veron, P., Charles, S., Vidal, P., Sola, M. S., Rundwasser, S., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.011 · Cited by 65
Self-citationGross, D., Tedesco, N., Leborgne, C., & Ronzitti, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.857276 · Cited by 64
Motas, S., Haurigot, V., Garcia, M., Marcó, S., Ribera, A., Roca, C., Sánchez, X., Sánchez, V., Molas, M., Bertolin, J., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.86696 · Cited by 63
Emerging Concepts and Challenges in Rheumatoid Arthritis Gene Therapy
Deviatkin, A. A., Vakulenko, Y. A., Akhmadishina, L. V., Tarasov, V. V., Beloukhova, M. I., Zamyatnin, A. A., & Lukashev, A. N. (2020) · Biomedicines · doi:10.3390/biomedicines8010009 · Cited by 63
Roth, T. L., & Marson, A. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012419-032626 · Cited by 69
Fidanacogene Elaparvovec: First Approval
Dhillon, S. (2024) · Drugs · doi:10.1007/s40265-024-02017-4 · Cited by 61
Efficient In Vivo Liver-Directed Gene Editing Using CRISPR/Cas9
Singh, K., Evens, H., Nair, N., Rincón, M. Y., Sarcar, S., Samara-Kuko, E., Chuah, M., & VandenDriessche, T. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.023 · Cited by 63
Benati, D., Miselli, F., Cocchiarella, F., Patrizi, C., Carretero, M., Baldassarri, S., Ammendola, V., Has, C., Colloca, S., Río, M. D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.024 · Cited by 64
Hemophilia gene therapy comes of age
George, L. A. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017009878 · Cited by 63
Fuchs, S. P., & Desrosiers, R. C. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.68 · Cited by 61
Hemophilia Gene Therapy: Approaching the First Licensed Product
Batty, P. A., & Lillicrap, D. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000540 · Cited by 61
Brown, D. A., Altermatt, M., Dobreva, T., Chen, S., Wang, A. Z., Thomson, M. W., & Gradinaru, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.730825 · Cited by 61
Adeno-Associated Virus Vectors: Principles, Practices, and Prospects in Gene Therapy
Zwi‐Dantsis, L., Mohamed, S., Massaro, G., & Moeendarbary, E. (2025) · Viruses · doi:10.3390/v17020239 · Cited by 68
Carvalho, M. A. B. R., Sepodes, B. M. N., & Martins, A. P. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00182 · Cited by 65
Complexity of immune responses to AAV transgene products – Example of factor IX
Herzog, R. W. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.05.006 · Cited by 60
Gene Therapy for Lysosomal Storage Disorders: Ongoing Studies and Clinical Development
Massaro, G., Geard, A. F., Liu, W., Coombe-Tennant, O., Waddington, S. N., Baruteau, J., Gissen, P., & Rahim, A. A. (2021) · Biomolecules · doi:10.3390/biom11040611 · Cited by 64
A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice
Merlin, S., Cannizzo, E. S., Borroni, E., Bruscaggin, V., Schinco, P., Tulalamba, W., Chuah, M., Arruda, V. R., VandenDriessche, T., Prat, M., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.029 · Cited by 61
Porro, F., Bortolussi, G., Barzel, A., Caneva, A. D., Iaconcig, A., Vodret, S., Zentilin, L., Kay, M. A., & Muro, A. F. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707601 · Cited by 62
Self-citationCurrent and emerging factor VIII replacement products for hemophilia A
Cafuir, L. A., & Kempton, C. L. (2017) · Therapeutic Advances in Hematology · doi:10.1177/2040620717721458 · Cited by 60
Delivery Approaches for Therapeutic Genome Editing and Challenges
Ates, I., Rathbone, T., Stuart, C., Bridges, P. H., & Cottle, R. N. (2020) · Genes · doi:10.3390/genes11101113 · Cited by 63
Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies
Chu, W. S., & Ng, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658038 · Cited by 59
Caneva, A. D., Porro, F., Bortolussi, G., Sola, R., Lisjak, M., Barzel, A., Giacca, M., Kay, M. A., Vlahoviček, K., Zentilin, L., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.128863 · Cited by 61
Self-citationWang, L., Breton, C. A., Warzecha, C. C., Bell, P. L., Yan, H., He, Z., White, J., Zhu, Y., Li, M., Buza, E. L., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.020 · Cited by 61
Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy
Samelson-Jones, B. J., & Arruda, V. R. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.007 · Cited by 58
Wang, Q., Zhong, X., Li, Q., Su, J., Liu, Y., Mo, L., Deng, H., & Yang, Y. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.025 · Cited by 60
Innate Immune Response to Viral Vectors in Gene Therapy
Wang, Y., & Shao, W. (2023) · Viruses · doi:10.3390/v15091801 · Cited by 65
AAV for Gene Therapy in Ocular Diseases: Progress and Prospects
He, X., Fu, Y., Ma, L., Yao, Y., Ge, S., Yang, Z. H., & Fan, X. (2023) · Research · doi:10.34133/research.0291 · Cited by 66
Hemophilia gene therapy comes of age
George, L. A. (2017) · Hematology · doi:10.1182/asheducation-2017.1.587 · Cited by 58
Restoring the natural tropism of AAV2 vectors for human liver
Cabanes‐Creus, M., Hallwirth, C. V., Westhaus, A., Ng, B. H., Liao, S. H. Y., Zhu, E., Navarro, R. G., Baltazar, G., Drouyer, M., Scott, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba3312 · Cited by 56
A versatile toolkit for overcoming AAV immunity
Li, X., Wei, X., Lin, J., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991832 · Cited by 57
The Role of Recombinant AAV in Precise Genome Editing
Bijlani, S., Pang, K. M., Sivanandam, V., Singh, A., & Chatterjee, S. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.799722 · Cited by 63
Gene Therapy for Mitochondrial Diseases: Current Status and Future Perspective
Donfrancesco, A. D., Massaro, G., Meo, I. D., Tiranti, V., Bottani, E., & Brunetti, D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061287 · Cited by 62
Zhang, C., Yao, T., Zheng, Y., Li, Z., Zhang, Q., Zhang, L., & Zhou, D. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.11.066 · Cited by 57
CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells
Kim, E. J., Kang, K. H., & Ju, J. H. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.198 · Cited by 58
Targeted in vivo knock-in of human alpha-1-antitrypsin cDNA using adenoviral delivery of CRISPR/Cas9
Stephens, C. J., Kashentseva, E. A., Everett, W., Kaliberova, L. N., & Curiel, D. T. (2018) · Gene Therapy · doi:10.1038/s41434-018-0003-1 · Cited by 57
Emerging biomaterials for downstream manufacturing of therapeutic proteins
Li, Y., Stern, D., Lock, L. L., Mills, J., Ou, B. S., Morrow, M., Xu, X., Ghose, S., Li, Z. J., & Cui, H. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.03.015 · Cited by 57
Aronson, S. J., Bakker, R. S., Shi, X., Duijst, S., ten Bloemendaal, L., de Waart, D. R., Verheij, J., Ronzitti, G., Elferink, R. P. J. O., Beuers, U. H., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.021 · Cited by 61
Yasuda, M., Huston, M. W., Pagant, S., Gan, L., Martin, S. S., Sproul, S., Richards, D., Ballaron, S. J., Hettini, K., Ledeboer, A., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.07.002 · Cited by 58
Impact of novel hemophilia therapies around the world
Ozelo, M. C., & Yamaguti-Hayakawa, G. G. (2022) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12695 · Cited by 59
Greig, J. A., Limberis, M. P., Bell, P., Chen, S.-J., Calcedo, R., Rader, D. J., & Wilson, J. M. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.014 · Cited by 56
Ilyinskii, P. O., Michaud, A. M., Roy, C. J., Rizzo, G. L., Elkins, S. L., Capela, T., Chowdhury, A. C., Leung, S. S., & Kishimoto, T. K. (2021) · Science Advances · doi:10.1126/sciadv.abd0321 · Cited by 56
Gene Therapy in Hemophilia: Recent Advances
Rodriguez-Merchan, E. C., Pablo-Moreno, J. A. D., & Liras, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147647 · Cited by 58
Paying for future success in gene therapy
Orkin, S. H., & Reilly, P. R. (2016) · Science · doi:10.1126/science.aaf4770 · Cited by 59
Huang, L., Low, A., Damle, S. S., Keenan, M. M., Kuntz, S., Murray, S., Monia, B. P., & Guo, S. (2018) · Genome biology · doi:10.1186/s13059-017-1386-9 · Cited by 57
Besse, A., Astord, S., Marais, T., Roda, M., Giroux, B., Lejeune, F., Relaix, F., Smeriglio, P., Barkats, M., & Biferi, M. G. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.011 · Cited by 53
Gene therapy for Duchenne muscular dystrophy
Ramos, J. N., & Chamberlain, J. S. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1088780 · Cited by 61
The progress of AAV-mediated gene therapy in neuromuscular disorders
Aguti, S., Malerba, A., & Zhou, H. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1479739 · Cited by 62
Advances in gene therapy for hemophilia: basis, current status, and future perspectives
Ohmori, T. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2513-4 · Cited by 60
Doerfler, P. A., Todd, A. G., Clément, N., Falk, D. J., Nayak, S., Herzog, R. W., & Byrne, B. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.103 · Cited by 55
Hemophilia A gene therapy: current and next-generation approaches
Pipe, S. W., Gonen-Yaacovi, G., & Segurado, O. G. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2002842 · Cited by 55
An Overview of Nonclinical and Clinical Liver Toxicity Associated With AAV Gene Therapy
Whiteley, L. O. (2023) · Toxicologic Pathology · doi:10.1177/01926233231201408 · Cited by 54
Gene therapy and peripheral nerve repair: a perspective
Hoyng, S. A., de Winter, F., Tannemaat, M. R., Blits, B., Malessy, M. J. A., & Verhaagen, J. (2015) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2015.00032 · Cited by 55
Boisgérault, F., & Mingozzi, F. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150630121750 · Cited by 54
Self-citationMattar, C. N. Z., Gil-Fariña, I., Rosales, C., Johana, N. B., Tan, Y., McIntosh, J., Kaeppel, C., Waddington, S. N., Biswas, A., Choolani, M. A., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.003 · Cited by 55
Self-citationWang, D., Zhong, L., Li, M., Li, J., Tran, K., Ren, L., He, R., Xie, J., Moser, R. P., Fraser, C. K., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.09.003 · Cited by 55
Welles, H. C., Jennewein, M. F., Mason, R. D., Narpala, S., Wang, L., Cheng, C., Zhang, Y., Todd, J.-P., Lifson, J. D., Balazs, A. B., et al. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1007395 · Cited by 53
Hudry, E., Aihara, F., Meseck, E. K., Mansfield, K. G., McElroy, C., Chand, D. H., Tukov, F. F., & Penraat, K. A. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.07.020 · Cited by 53
Autophagy determines efficiency of liver‐directed gene therapy with adeno‐associated viral vectors
Hösel, M., Huber, A., Bohlen, S., Lucifora, J., Ronzitti, G., Puzzo, F., Boisgérault, F., Hacker, U. T., Kwanten, W. J., Klöting, N., et al. (2017) · Hepatology · doi:10.1002/hep.29176 · Cited by 56
Self-citationNext-generation AAV vectors for clinical use: an ever-accelerating race
Weinmann, J., & Grimm, D. (2017) · Virus Genes · doi:10.1007/s11262-017-1502-7 · Cited by 54
Leborgne, C., Latournerie, V., Boutin, S., Desgue, D., Quéré, A., Pignot, E., Collaud, F., Charles, S., Sola, M. S., Masat, E., et al. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.03.004 · Cited by 53
Self-citationApproach for in vivo delivery of CRISPR/Cas system: a recent update and future prospect
Chuang, Y.-F., Phipps, A. J., Lin, F., Hecht, V. F. G., Hewitt, A. W., Wang, P., & Liu, G. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03725-2 · Cited by 53
Fletcher, S. J., Jenner, K., Pembroke, L., Holland, M., & Khair, K. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02256-2 · Cited by 57
Weber, N. D., Odriozola, L., Martínez-García, J., Ferrer, V., Douar, A. M., Bénichou, B., González‐Aseguinolaza, G., & Smerdou, C. (2019) · Nature Communications · doi:10.1038/s41467-019-13614-3 · Cited by 52
Discussing investigational AAV gene therapy with hemophilia patients: A guide
Sidonio, R. F., Pipe, S. W., Callaghan, M. U., Valentino, L. A., Monahan, P. E., & Croteau, S. E. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100759 · Cited by 52
Controlled release strategies for rAAV-mediated gene delivery
Rey‐Rico, A., & Cucchiarini, M. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.10.015 · Cited by 52
Yadak, R., Smitt, P. A. E. S., van Gisbergen, M. W., van Til, N. P., & de Coo, I. F. M. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00031 · Cited by 54
Roca, C., Motas, S., Marcó, S., Ribera, A., Sánchez, V., Sánchez, X., Bertolin, J., León, X., Pérez, J., Garcia, M., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx058 · Cited by 53
Brooks, A., Futrega, K., Liang, X., Hu, X., Liu, X., Crawford, D. H., Doran, M. R., Roberts, M. S., & Wang, H. (2017) · Stem Cells Translational Medicine · doi:10.1002/sctm.17-0209 · Cited by 52
World Federation of Hemophilia Gene Therapy Registry
Konkle, B. A., Coffin, D., Pierce, G. F., Clark, C., George, L. A., Iorio, A., Mahlangu, J. N., Naccache, M., O’Mahony, B., Peyvandi, F., et al. (2020) · Haemophilia · doi:10.1111/hae.14015 · Cited by 53
Milani, M., Canepari, C., Liu, T., Biffi, M., Russo, F., Plati, T., Curto, R., Patarroyo-White, S. L., Drager, D., Visigalli, I., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30102-3 · Cited by 50
Burdett, T., & Nuseibeh, S. (2022) · Gene Therapy · doi:10.1038/s41434-022-00363-0 · Cited by 52
Helper-dependent adenoviral vectors for liver-directed gene therapy of primary hyperoxaluria type 1
Castello, R., Borzone, R., D’Aria, S., Annunziata, P., Piccolo, P., & Brunetti‐Pierri, N. (2015) · Gene Therapy · doi:10.1038/gt.2015.107 · Cited by 51
Recent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia
Ajufo, E., & Cuchel, M. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0579-0 · Cited by 51
Wang, M., Sun, J., Crosby, A. J., Woodard, K., Hirsch, M. L., Samulski, R. J., & Li, C. (2016) · Gene Therapy · doi:10.1038/gt.2016.75 · Cited by 52
Metadata
- Authors
- Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., Riddell, A., Pie, J., Rangarajan, S., Bevan, D., Recht, M., Shen, Y.-M., Halka, K. G., Basner-Tschakarjan, E., Mingozzi, F., High, K. A., Allay, J., Kay, M. A., Ng, C. Y. C., Zhou, J., Cancio, M., Morton, C. L., Gray, J. T., Srivastava, D., Nienhuis, A. W., & Davidoff, A. M.
- Affiliations
- NHS Blood and Transplant (GB)
- Royal Free London NHS Foundation Trust (GB)
- University College London (GB)
- St Thomas' Hospital (GB)
- Oregon Health & Science University (US)
- The University of Texas Southwestern Medical Center (US)
- Children's Hospital of Philadelphia (US)
- St. Jude Children's Research Hospital (US)
- Stanford Medicine (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-11-20
- Volume
- 371
- Issue
- 21
- Pages
- 1994-2004
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4278802
- OpenAlex
- W1969271703
- Cited by
- 1,273
- References
- 17
- Citations by year
- 2026: 44 · 2025: 64 · 2024: 80 · 2023: 99 · 2022: 118 · 2021: 119 · 2020: 133 · 2019: 125 · 2018: 139 · 2017: 144 · 2016: 108 · 2015: 92 · 2014: 2
- FWCI
- 81.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Assisi Foundation of Memphis
- NHS Blood and Transplant
- American Lebanese Syrian Associated Charities
- National Institute for Health and Care Research (RP-PG-0310-1001, NF-SI-0513-10071)
- University College London
- University College London Hospitals NHS Foundation Trust
- Medical Research Council
- National Heart, Lung, and Blood Institute (HL094396, R01HL094396, R01HL073838, R01HL064274)
- National Cancer Institute (P30CA021765)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- hemophilia B, AAV8 vector, self-complementary AAV, dose-response relationship, long-term safety, late toxicity, alanine aminotransferase elevation, bleeding events
- MeSH terms
- Dependovirus, Adult, Alanine Transaminase, Hemophilia B, Factor IX, Follow-Up Studies, Genetic Vectors, Humans, Infusions, Intravenous, Male, Middle Aged, Genetic Therapy, Gene Expression, Transgenes, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
